DE60228330D1 - Kondensierte heterocyclische verbindungen und deren analoga; modulatoren der funktion von nukleären hormonrezeptoren - Google Patents

Kondensierte heterocyclische verbindungen und deren analoga; modulatoren der funktion von nukleären hormonrezeptoren

Info

Publication number
DE60228330D1
DE60228330D1 DE60228330T DE60228330T DE60228330D1 DE 60228330 D1 DE60228330 D1 DE 60228330D1 DE 60228330 T DE60228330 T DE 60228330T DE 60228330 T DE60228330 T DE 60228330T DE 60228330 D1 DE60228330 D1 DE 60228330D1
Authority
DE
Germany
Prior art keywords
nuclear
hormonic
modulators
analogue
receptors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60228330T
Other languages
German (de)
English (en)
Inventor
Mark E Salvati
James Aaron Balog
Dacia A Pickering
Hong Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of DE60228330D1 publication Critical patent/DE60228330D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/72—4,7-Endo-alkylene-iso-indoles
    • C07D209/74—4,7-Endo-alkylene-iso-indoles with an oxygen atom in position 1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/72—4,7-Endo-alkylene-iso-indoles
    • C07D209/76—4,7-Endo-alkylene-iso-indoles with oxygen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE60228330T 2001-12-19 2002-12-18 Kondensierte heterocyclische verbindungen und deren analoga; modulatoren der funktion von nukleären hormonrezeptoren Expired - Lifetime DE60228330D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34196201P 2001-12-19 2001-12-19
PCT/US2002/040737 WO2003053358A2 (en) 2001-12-19 2002-12-18 Fused heterocyclic compounds and analogs thereof: modulators of nuclear hormone receptor function

Publications (1)

Publication Number Publication Date
DE60228330D1 true DE60228330D1 (de) 2008-09-25

Family

ID=23339743

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60228330T Expired - Lifetime DE60228330D1 (de) 2001-12-19 2002-12-18 Kondensierte heterocyclische verbindungen und deren analoga; modulatoren der funktion von nukleären hormonrezeptoren

Country Status (10)

Country Link
US (3) US7087636B2 (enExample)
EP (1) EP1467979B1 (enExample)
JP (1) JP4434740B2 (enExample)
AT (1) ATE404544T1 (enExample)
AU (1) AU2002364082A1 (enExample)
DE (1) DE60228330D1 (enExample)
ES (1) ES2310622T3 (enExample)
HU (1) HUP0500096A3 (enExample)
PL (1) PL206962B1 (enExample)
WO (1) WO2003053358A2 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7001911B2 (en) * 2000-06-28 2006-02-21 Bristol-Myers Squibb Company Fused cyclic modulators of nuclear hormone receptor function
US20040077605A1 (en) * 2001-06-20 2004-04-22 Salvati Mark E. Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
EP1854798A3 (en) * 2000-09-19 2007-11-28 Bristol-Myers Squibb Company Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US20040087548A1 (en) * 2001-02-27 2004-05-06 Salvati Mark E. Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
AU2002364082A1 (en) * 2001-12-19 2003-07-09 Bristol-Myers Squibb Company Fused heterocyclic compounds and analogs thereof: modulators of nuclear hormone receptor function
FR2860793A1 (fr) * 2003-10-14 2005-04-15 Entomed Composes derives de norcantharidine, leurs procedes de preparation, les compositions les contenant et leurs utilisations
CA2549053C (en) 2003-12-19 2012-08-28 Eli Lilly And Company Tricyclic steroid hormone nuclear receptor modulators
CA2568640C (en) 2004-06-04 2011-08-09 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
CA2569964A1 (en) * 2004-06-10 2005-12-29 Duramed Pharmaceuticals, Inc. Formulations of sumatriptan for absorption across biological membranes, and methods of making and using the same
SE0500055D0 (sv) * 2005-01-10 2005-01-10 Astrazeneca Ab Therapeutic agents 3
US7776859B2 (en) * 2005-10-14 2010-08-17 Bristol-Myers Squibb Company Hexahydroimidazopyrazin-3-one compounds useful as modulators of androgen receptor function
CA2635541A1 (en) * 2005-12-28 2007-07-12 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds and their use as mineralocorticoid receptor ligands
US7468439B2 (en) * 2006-09-06 2008-12-23 Bristol-Myers Squibb Company Alkylene bridged sultam compounds useful as modulators of nuclear hormone receptor function
WO2008064136A2 (en) * 2006-11-17 2008-05-29 Acadia Pharmaceuticals Inc. Compounds with activity at retinoic acid receptors
EP2170899A1 (en) * 2007-06-27 2010-04-07 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as modulators of nuclear hormone receptor function
US8466171B2 (en) 2007-11-01 2013-06-18 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as modulators of nuclear hormone receptor function
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
CA2947767A1 (en) 2014-05-22 2015-11-26 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (161)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3320270A (en) 1963-10-08 1967-05-16 Tri Kem Corp Certain 2-acylimidothiazole compounds
US3215597A (en) 1963-10-30 1965-11-02 Dow Chemical Co Methods and compositions for use in animal husbandry
US3343940A (en) 1964-06-12 1967-09-26 Pennsalt Chemicals Corp Process for plant desiccation
US3261845A (en) * 1964-07-14 1966-07-19 Dow Chemical Co N-phenyl derivatives of 3,6-epoxyhexahydrophthalimide
GB1039020A (en) 1964-09-21 1966-08-17 Biorex Laboratories Ltd Process for the preparation of 5-nitrofurfuraldehyde diacetate
US3428538A (en) 1966-01-13 1969-02-18 Peter Scheiner Method for preparing aziridines by photolysis of triazolines
JPS4916937B1 (enExample) 1970-01-21 1974-04-25
US3821232A (en) 1971-12-20 1974-06-28 Petrolite Corp 1,2-dihydro-pyridine-n-phosphonates and thiophosphonates
US3965264A (en) 1971-12-20 1976-06-22 Petrolite Corporation Process for controlling microbiological organisms in aqueous or petroleum hydrocarbon systems
US3998833A (en) 1971-12-20 1976-12-21 Petrolite Corporation Diels-alder adducts of dihydro-nitrogen heterocyclic phosphoramidates
US3923490A (en) 1971-12-20 1975-12-02 Petrolite Corp Use of 1,2-dihydro-pyridine-N-phosphonates and thiophosphonates as microbiocides
US4089650A (en) 1971-12-20 1978-05-16 Petrolite Corporation Use of Diels-Alder adducts of dihydro-nitrogen heterocyclic phosphoramidates as corrosion inhibitors
JPS5032306B2 (enExample) 1972-11-02 1975-10-20
US3925554A (en) 1972-11-30 1975-12-09 Sumitomo Chemical Co Certain 3,5-dichlorophenyl compound used as a plant fungicide
NL7501563A (nl) 1974-02-28 1975-09-01 Merck & Co Inc Werkwijze voor het bereiden van preparaten te- gen het samenpakken van bloedplaatjes.
US3997293A (en) 1974-03-19 1976-12-14 Petrolite Corporation Use of dihydro-nitrogen heterocyclic phosphoramidates as corrosion inhibitors
JPS5188631U (enExample) 1975-01-10 1976-07-15
FR2329276A1 (fr) 1975-10-29 1977-05-27 Roussel Uclaf Nouvelles imidazolidines substituees, procede de preparation, application comme medicament et compositions les renfermant
JPS5386035U (enExample) 1976-12-16 1978-07-15
DE2862100D1 (en) 1977-10-12 1983-01-05 Ici Plc Acylanilides, process for their manufacture and pharmaceutical and veterinary compositions containing them
MC1220A1 (fr) 1977-10-28 1979-07-20 Hoffmann La Roche Nouveaux derives d'imidazolidine
CA1138334A (en) 1977-10-28 1982-12-28 Karl Bernauer Pharmaceutical preparations containing certain urea derivatives
US4191775A (en) 1977-12-15 1980-03-04 Imperial Chemical Industries Limited Amide derivatives
FR2465486A1 (fr) 1979-09-21 1981-03-27 Roussel Uclaf Nouvelle application utilisant la lh-rh ou des agonistes
JPS5663961A (en) * 1979-10-05 1981-05-30 Tsutomu Kameyama Novel isoindoline derivative and its preparation
JPS5663961U (enExample) 1979-10-24 1981-05-29
FR2492381A1 (fr) 1980-10-21 1982-04-23 Science Union & Cie Nouveaux acides aza bicyclo alcane carboxyliques substitues leurs procedes de preparation et leur emploi comme inhibiteur d'enzyme
DE3121152A1 (de) 1981-05-22 1982-12-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen "verwendung der kombination eines aromatase-hemmers mit einem antiandrogen zur prophylaxe und therapie der prostatahyperplasie"
US4753957A (en) 1981-09-28 1988-06-28 Rohm And Haas Company Substituted 2,4-imidazolidinediones and fungicidal compositions
US5446120A (en) 1985-10-07 1995-08-29 The Boeing Company Polyethersulfone oligomers and blends
US5512676A (en) 1987-09-03 1996-04-30 The Boeing Company Extended amideimide hub for multidimensional oligomers
US4851495A (en) * 1987-02-20 1989-07-25 The Boeing Company Polyetherimide oligomer
US5155206A (en) 1987-09-03 1992-10-13 The Boeing Company Crosslinkable polyamideimide oligomers and a method of preparation
US5693741A (en) 1988-03-15 1997-12-02 The Boeing Company Liquid molding compounds
US5367083A (en) 1987-09-03 1994-11-22 The Boeing Company Extended acid halide capping monomers
US5210213A (en) 1983-06-17 1993-05-11 The Boeing Company Dimensional, crosslinkable oligomers
US5516876A (en) 1983-09-27 1996-05-14 The Boeing Company Polyimide oligomers and blends
US5780583A (en) 1991-01-09 1998-07-14 The Boeing Company Reactive polyarylene sulfide oligomers
US4584364A (en) 1984-02-06 1986-04-22 The Boeing Company Phenolic-capped imide sulfone resins
US5116935A (en) 1987-05-04 1992-05-26 The Boeing Company Polyimide oligomers and blends and method of curing
US5645925A (en) 1988-03-14 1997-07-08 Boeing Company Advanced composite blends
US5286811A (en) 1983-09-27 1994-02-15 The Boeing Company Blended polyimide oligomers and method of curing polyimides
US5104967A (en) 1987-09-03 1992-04-14 The Boeing Company Amideimide oligomers and blends
US4536559A (en) 1983-06-17 1985-08-20 The Boeing Company Thermally stable polyimide polysulfone compositions for composite structures
US4507303A (en) 1981-12-22 1985-03-26 Sumitomo Chemical Company, Limited Succinimide derivatives, compositions and method of use
EP0091596B1 (de) 1982-04-08 1991-09-11 Shell Internationale Researchmaatschappij B.V. Neue Hydantoine, ihre Herstellung und Verwendung
DE3227055A1 (de) 1982-07-20 1984-01-26 Hoechst Ag, 6230 Frankfurt Neue derivate der 2-aza-bicyclo(2.2.2)octan-3-carbonsaeure, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung sowie 2-aza-bicyclo(2.2.2)octan-3-carbonsaeure als zwischenstufe und verfahren zu deren herstellung
US4473393A (en) 1982-08-06 1984-09-25 Buffalo Color Corporation Pesticidal thiohydantoin compositions
JPS59118750A (ja) 1982-12-27 1984-07-09 Eisai Co Ltd カルボン酸アミド化合物およびその誘導体
US5112939A (en) 1983-06-17 1992-05-12 The Boeing Company Oligomers having pyrimidinyl end caps
US4980481A (en) 1983-06-17 1990-12-25 The Boeing Company End-cap monomers and oligomers
US4476184A (en) * 1983-08-09 1984-10-09 The Boeing Company Thermally stable polysulfone compositions for composite structures
US4582886A (en) * 1984-02-27 1986-04-15 General Electric Company Heat curable epoxy resin compositions and epoxy resin curing agents
US4562255A (en) * 1984-03-30 1985-12-31 American Home Products Corporation Substituted bi-alicyclic imides
US4533737A (en) * 1984-04-02 1985-08-06 General Electric Company Silicon functionalized norbornane carboxyimide and methods for making
JPS60168906U (ja) 1984-04-19 1985-11-09 株式会社フジクラ 微小径孔を有するセラミツク成形体の成形用型枠
GB8411928D0 (en) 1984-05-10 1984-06-13 Robinson Bros Ltd Preparing substituted oxazolines
DE3417516A1 (de) * 1984-05-11 1985-11-14 Zinser Textilmaschinen Gmbh, 7333 Ebersbach Streckwerk einer spinnmaschine
US4666885A (en) 1985-02-08 1987-05-19 Fernand Labrie Combination therapy for treatment of female breast cancer
US4760053A (en) 1984-08-02 1988-07-26 Fernand Labrie Combination therapy for selected sex steroid dependent cancers
US4659695A (en) 1985-02-08 1987-04-21 Fernand Labrie Method of treatment of prostate cancer
US4775660A (en) 1984-08-02 1988-10-04 Fernand Labrie Treatment of breast cancer by combination therapy
US4670536A (en) 1985-06-01 1987-06-02 Director-General Of Agency Of Industrial Science And Technology Addition-curable quinoxaline resin oligomer and intermediate material for fiber-reinforced composite
US4656235A (en) 1985-09-05 1987-04-07 Polytechnic Institute Of New York Siloxane-containing polyimide coatings for electronic devices
US5610317A (en) 1985-09-05 1997-03-11 The Boeing Company Multiple chemically functional end cap monomers
US5594089A (en) 1985-09-05 1997-01-14 The Boeing Company Heterocycle or heterocycle sulfone oligomers with multiple chemically functional end caps
US5151487A (en) 1985-09-30 1992-09-29 The Boeing Company Method of preparing a crosslinking oligomer
US4892943A (en) 1985-10-16 1990-01-09 American Home Products Corporation Fused bicyclic imides with psychotropic activity
GB8617653D0 (en) 1986-07-18 1986-08-28 Ici Plc Amide derivatives
US5084472A (en) 1986-11-04 1992-01-28 Roussel Application of 1-(3'-trifluoromethyl-4'-nitrophenyl)-4,4'-dimethylimidazoline 2,5-dione in the treatment of hormone-dependent cancers other than that of the prostate
US4833249A (en) * 1987-03-05 1989-05-23 American Home Products Corporation Isothiazolone 1,1-dioxide derivatives with psychotropic activity
JPS63170383U (enExample) 1987-04-27 1988-11-07
FR2619381B1 (fr) 1987-08-13 1989-12-08 Roussel Uclaf Nouvelles imidazolidines substituees par un radical hydroxymethyle et un radical phenyl substitue, leur procede de preparation, leur application comme medicaments, les compositions pharmaceutiques les renfermant et un intermediaire pour leur preparation
US4892578A (en) 1987-11-06 1990-01-09 Fmc Corporation Phenylmethyl-4,4-dimethyl-3-isoxazolidinone plant regulators
JPH01125381A (ja) 1987-11-11 1989-05-17 Hitachi Ltd 付加反応型イミド系化合物、およびその樹脂組成物、およびその製造方法
US5817744A (en) 1988-03-14 1998-10-06 The Boeing Company Phenylethynyl capped imides
US5595985A (en) 1989-03-10 1997-01-21 Endorecherche Inc. Combination therapy for prophylaxis and/or treatment of benign prostatic hyperplasia
AU5281990A (en) 1989-03-10 1990-10-09 Endorecherche Inc. Combination therapy for treatment of estrogen sensitive diseases
FR2649110B1 (fr) 1989-06-29 1994-10-21 Adir Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DK0943328T3 (da) 1989-07-07 2004-10-18 Endorech Inc Kombinationsterapi til profylakse og/eller behandling af godartet prostatahyperplasi
WO1991006297A1 (en) 1989-10-27 1991-05-16 The Du Pont Merck Pharmaceutical Company (n-phthalimidoalkyl) piperidines
FR2656302B1 (fr) 1989-12-22 1992-05-07 Roussel Uclaf Nouveau procede de preparation de l'anandron et derives de l'anandron.
US5114612A (en) 1990-04-04 1992-05-19 The United States Of America As Represented By The Department Of Energy Liquid crystal polyester thermosets
JP2800953B2 (ja) 1990-07-06 1998-09-21 住友製薬株式会社 新規なイミド誘導体
US5093500A (en) 1990-10-17 1992-03-03 Shell Oil Company Spirodilactam bisimides
HUT62296A (en) 1990-12-18 1993-04-28 Sandoz Ag Herbicidal composition comprising hydantoin derivative as active ingredient and process for producing the active ingredient
FR2671348B1 (fr) 1991-01-09 1993-03-26 Roussel Uclaf Nouvelles phenylimidazolidines, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant.
US5411981A (en) 1991-01-09 1995-05-02 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
USRE35956E (en) 1991-01-09 1998-11-10 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
FR2694290B1 (fr) 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines éventuellement substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
IL107719A0 (en) 1992-12-21 1994-02-27 Du Pont Imidazolones their manufacture and their use as herbicides
DE59306670D1 (de) 1993-02-17 1997-07-10 New Sulzer Diesel Ag Brennstoffeinspritzventil für eine Hubkolbenbrennkraftmaschine
US5817679A (en) * 1993-04-01 1998-10-06 University Of Virginia 7-Azabicyclo 2.2.1!-heptane and -heptene derivatives as cholinergic receptor ligands
US5399725A (en) 1993-05-27 1995-03-21 Bristol-Myers Squibb Co. 7-oxabicycloheptane carboxylic acid prostaglandin analog intermediates useful in the preparation of anti-thrombotic and anti-vasospastic compounds and method for preparing same
JP3429851B2 (ja) 1993-06-10 2003-07-28 三井化学株式会社 感熱記録材料
TW521073B (en) 1994-01-05 2003-02-21 Hoechst Marion Roussel Inc New optionally substituted phenylimidazolidines, their preparation process, their use as anti-androgenic agent and the pharmaceutical compositions containing them
FR2716110B1 (fr) 1994-02-16 1996-04-05 Roussel Uclaf Compositions cosmétiques ou pharmaceutiques comprenant des liposomes.
US5539126A (en) 1994-04-20 1996-07-23 Bristol-Myers Squibb Company Method for preparing homochiral maleimide intermediates, via silylation techniques
GB9411800D0 (en) 1994-06-13 1994-08-03 Sandoz Ltd Organic compounds
CA2200085A1 (en) 1994-09-14 1996-03-21 Andrew Guy Messenger Control of hair growth
CZ176197A3 (cs) 1994-12-22 1998-09-16 Ligand Pharmaceuticals Incorporated Modulátory steroidových receptorů a způsoby jejich přípravy a použití
DE69636677D1 (de) 1995-12-13 2006-12-14 Univ California Kristalle der mit einem Ligand komplexierten Ligandenbindedomäne des Schilddrüsenhormonrezeptors
FR2742749B1 (fr) 1995-12-22 1998-02-06 Roussel Uclaf Nouvelles phenylimidazolidines comportant notamment un radical nitrooxy ou carbonyloxy, procede et intermediaires de preparation, application comme medicaments, nouvelles utilisations et compositions pharmaceutiques
US6673927B2 (en) 1996-02-16 2004-01-06 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Farnesyl transferase inhibitors
US6017924A (en) 1996-06-27 2000-01-25 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
RU2214412C2 (ru) 1996-06-27 2003-10-20 Лиганд Фармасетикалз Инкорпорейтед ПРОИЗВОДНЫЕ 8-ПИРИДОНО [5,6g] ХИНОЛИНА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБЫ С ИХ ИСПОЛЬЗОВАНИЕМ
US6448443B1 (en) 1996-10-16 2002-09-10 President And Fellows Of Harvard College Synthesis of combinatorial libraries of compounds reminiscent of natural products
WO1998016830A2 (en) 1996-10-16 1998-04-23 The President And Fellows Of Harvard College Droplet assay system
EP0947513B1 (en) 1996-10-25 2004-05-19 Daiichi Pharmaceutical Co., Ltd. Tricyclic amine derivatives
US6071957A (en) 1996-11-27 2000-06-06 The University Of Tennessee Research Corporation Irreversible non-steroidal antagonist compound and its use in the treatment of prostate cancer
US5929146A (en) 1996-12-27 1999-07-27 Minnesota Mining And Manufacturing Company Modifying agents for polyolefins
CN1217660C (zh) 1997-01-23 2005-09-07 史密丝克莱恩比彻姆公司 Il－8受体拮抗剂
SK117499A3 (en) 1997-03-03 2000-05-16 Boehringer Ingelheim Pharma Small molecules useful in the treatment of inflammatory and immune cell-mediated diseases, small molecules and pharmaceutical composition with their content
US6054487A (en) 1997-03-18 2000-04-25 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
EP0979407A1 (en) 1997-04-29 2000-02-16 The Salk Institute For Biological Studies Methods for identifying ligands for nuclear hormone receptors
FR2764890B1 (fr) 1997-06-24 1999-08-27 Adir Nouveaux derives chromeniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CA2294117A1 (en) 1997-07-03 1999-01-14 Dupont Pharmaceuticals Company Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders
AU751496B2 (en) 1997-08-28 2002-08-15 Vela Pharmaceuticals Inc. Androgen activity antagonists as therapies for anorexia, anorexia nervosa, and disorders characterized by a pathologically underweight condition
US7101681B1 (en) 1997-11-21 2006-09-05 Amgen, Inc. Nuclear hormone receptor drug screens
US6542352B1 (en) * 1997-12-09 2003-04-01 Daniel Devoe Ceramic chip capacitor of conventional volume and external form having increased capacitance from use of closely spaced interior conductive planes reliably connecting to positionally tolerant exterior pads through multiple redundant vias
CA2315715C (en) 1997-12-22 2010-06-22 Bayer Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
US6573218B1 (en) 1998-09-09 2003-06-03 Ishihara Sangyo Kaisha, Ltd. Fused-benzene derivatives useful as herbicides
US6297380B1 (en) 1998-11-23 2001-10-02 Pfizer Inc. Process and intermediates for growth hormone secretagogues
DE69909947T2 (de) 1998-12-02 2004-02-12 Nippon Paper Industries Co. Ltd. Tintenstrahlaufzeichnungsblatt mit einer Bildschutzschicht
JP2000169474A (ja) 1998-12-07 2000-06-20 Kotobuki Seiyaku Kk イソキヌクリジン誘導体及びその製造方法並びにこれを含有する高コレステロール血症治療剤
US6184249B1 (en) 1998-12-18 2001-02-06 Biophysica, Inc. Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes
EP1140943B1 (en) 1998-12-22 2003-08-13 Eli Lilly And Company Substituted pyrroloindoles
SI1140941T1 (en) 1998-12-23 2005-04-30 Bristol-Myers Squibb Pharma Company Nitrogen containing heterobicycles as factor xa inhibitors
CA2375797A1 (en) * 1999-06-11 2000-12-21 Allergan Sales, Inc. Organosilyl compounds having nuclear hormone receptor modulating activity
WO2001007052A1 (en) 1999-07-21 2001-02-01 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammatory disease
GB9918962D0 (en) 1999-08-11 1999-10-13 Cerebrus Ltd Chemical compounds xxii
AU6941200A (en) 1999-08-27 2001-03-26 Ligand Pharmaceuticals Incorporated 8-substituted-6-trifluoromethyl-9-pyrido(3,2-g)quinoline compounds as androgen receptor modulators
CZ2002711A3 (cs) 1999-08-27 2003-11-12 Ligand Pharmaceuticals Incorporated Modulátory androgenních receptorů, způsoby jejich výroby a způsoby jejich použití
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
GB9921150D0 (en) 1999-09-07 1999-11-10 Merck Sharp & Dohme Therapeutic agents
ATE309250T1 (de) 1999-09-10 2005-11-15 Novo Nordisk As Modulatoren der protein tyrosin phosphatase (ptpases)
CA2382919C (en) 1999-10-08 2008-12-09 Gruenenthal Gmbh Bicyclic imidazo-3-yl-amine derivatives
US6795776B1 (en) 1999-10-14 2004-09-21 Bristol-Myers Squibb Company Crystallographic structure of the androgen receptor ligand binding domain
WO2001030781A2 (en) 1999-10-20 2001-05-03 Tanabe Seiyaku Co., Ltd. INHIBITORS OF αLβ2 MEDIATED CELL ADHESION
US6200573B1 (en) 1999-12-03 2001-03-13 Starcor Pharmaceuticals, Inc. Method of medical management for lower urinary tract symptoms and benign prostatic hyperplasia
US6403588B1 (en) 2000-04-27 2002-06-11 Yamanouchi Pharmaceutical Co., Ltd. Imidazopyridine derivatives
CA2413417A1 (en) 2000-06-28 2002-01-03 Bristol-Myers Squibb Company Selective androgen receptor modulators and methods for their identification, design and use
US7001911B2 (en) 2000-06-28 2006-02-21 Bristol-Myers Squibb Company Fused cyclic modulators of nuclear hormone receptor function
US20040077605A1 (en) 2001-06-20 2004-04-22 Salvati Mark E. Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US20030114420A1 (en) 2000-06-28 2003-06-19 Salvati Mark E. Fused cyclic modulators of nuclear hormone receptor function
JP2004515462A (ja) * 2000-06-28 2004-05-27 ブリストル−マイヤーズ スクイブ カンパニー 核ホルモン・レセプタ機能のモジュレーターとしての縮合環式化合物
CN1995039A (zh) 2000-09-19 2007-07-11 布里斯托尔-迈尔斯斯奎布公司 核激素受体功能的调节剂稠合杂环琥珀酰亚胺化合物及其类似物
US6953679B2 (en) 2000-09-19 2005-10-11 Bristol-Myers Squibb Company Method for the preparation of fused heterocyclic succinimide compounds and analogs thereof
US6710048B2 (en) 2000-09-20 2004-03-23 Ortho-Mcneil Pharmaceutical, Inc. Pyrazine derivatives as modulators of tyrosine kinases
US6545017B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Urea substituted imidazopyridines
FR2818277B1 (fr) 2000-12-14 2003-01-24 Servier Lab Nouveaux derives bicycliques d'amino-pyrazinones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US20040087548A1 (en) 2001-02-27 2004-05-06 Salvati Mark E. Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
OA12552A (en) 2001-03-09 2006-06-06 Pfizer Prod Inc Triazolopyridines as anti-inflammatory agents.
US6750225B2 (en) 2001-04-18 2004-06-15 Bristol-Myers Squibb Pharms Company 1,4,5,6-tetrahydropyrazolo-[3,4,-c]-pyridin-7-ones useful as factor Xa inhibitors
EP1414795A4 (en) 2001-07-31 2006-03-01 Bristol Myers Squibb Co BICYCLIC MODULATORS OF THE FUNCTION OF THE ANDROGEN RECEPTOR
TWI263640B (en) 2001-12-19 2006-10-11 Bristol Myers Squibb Co Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
AU2002364082A1 (en) * 2001-12-19 2003-07-09 Bristol-Myers Squibb Company Fused heterocyclic compounds and analogs thereof: modulators of nuclear hormone receptor function
TW200407324A (en) 2002-05-17 2004-05-16 Bristol Myers Squibb Co Bicyclic modulators of androgen receptor function
US7405234B2 (en) 2002-05-17 2008-07-29 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
EP1534707B9 (en) 2002-06-19 2008-11-26 Janssen Pharmaceutica N.V. Substituted 2,4-dihydro-pyrrolo (3, 4-b) -quinolin-9-one derivatives useful as phosphodiesterase inhibitors
US6710334B1 (en) * 2003-01-20 2004-03-23 Genspec Sa Quadrupol ion trap mass spectrometer with cryogenic particle detector

Also Published As

Publication number Publication date
US7087636B2 (en) 2006-08-08
US7342034B2 (en) 2008-03-11
US20030181728A1 (en) 2003-09-25
US7291637B2 (en) 2007-11-06
ES2310622T3 (es) 2009-01-16
AU2002364082A1 (en) 2003-07-09
HUP0500096A2 (hu) 2005-05-30
EP1467979A4 (en) 2006-03-15
WO2003053358A3 (en) 2003-10-02
EP1467979B1 (en) 2008-08-13
US20050187273A1 (en) 2005-08-25
HUP0500096A3 (en) 2012-08-28
PL371191A1 (en) 2005-06-13
PL206962B1 (pl) 2010-10-29
ATE404544T1 (de) 2008-08-15
JP2005518382A (ja) 2005-06-23
AU2002364082A8 (en) 2003-07-09
WO2003053358A2 (en) 2003-07-03
JP4434740B2 (ja) 2010-03-17
US20060020002A1 (en) 2006-01-26
EP1467979A2 (en) 2004-10-20

Similar Documents

Publication Publication Date Title
DE60228330D1 (de) Kondensierte heterocyclische verbindungen und deren analoga; modulatoren der funktion von nukleären hormonrezeptoren
DE60230920D1 (de) Kondensierte zyklische modulatoren der funktion von nuklearen hormonrezeptoren
TWI263640B (en) Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
MY138531A (en) Fused heterocyclic succinmide compounds and analogs thereof, modulators of nuclear hormone receptor function
NO20026167D0 (no) Kondenserte cykliske forbindelser som modulatorer av nukle¶r hormon reseptor funksjon
DK1539166T3 (da) Farmaceutiske sammensætninger indeholdende dextromethorphan og quinidin til behandling af neurologiske sygdomme
CA2366932A1 (en) Cyclic protein tyrosine kinase inhibitors
ATE409181T1 (de) Proteomimetische verbindungen und verfahren
ATE387435T1 (de) Substituirte benzosulfonamide als potenzierungsmittel von glutamatrezeptoren
EA200101005A1 (ru) Высокоэффективные композиции, содержащие дигидроэрготамин
PL313075A1 (en) Heterocyclic compounds used as antagonistic substances in respect to neurokinin
ATE349443T1 (de) N-(4-(4-methylthiazol-5-yl)pyrimidin-2-yl)-n- phenylamine als antiproliferative verbindungen
DE60325985D1 (de) Substituierte bizyklische thiophen-derivate, diese verbindungen enthaltende zusammensetzungen und anwendungsverfahren
DE60329968D1 (de) Dosierungsformen enthaltend Thyroidhormone und deren Herstellungsverfahren
ATE266722T1 (de) Zyklische peptidomimetische urokinaserezeptorantagonisten
ATE384066T1 (de) Thieno-pyrrole verbindungen als antagonisten der gonadotropin-freisetzenden hormonrezeptoren
PL366565A1 (en) Fused cyclic modulators of nuclear hormone receptor function
EP1854798A3 (en) Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
BR0107179A (pt) Amidinas cìclicas e acìclicas e composições farmacêuticas contendo as mesmas para uso como agentes de ligação de receptor de progesterona
AR036257A1 (es) Sulfamatos de 2-alcoxiestradiol de accion antitumoral

Legal Events

Date Code Title Description
8364 No opposition during term of opposition